Skip to main content
رجوع
Watch Compare

Protalix BioTherapeutics, Inc.

جودة البيانات: 100%
PLX
NYSE Manufacturing Chemicals
KWD 2.29
▲ KWD 0.04 (1.56%)
القيمة السوقية: 184.11 M
السعر
KWD 2.29
القيمة السوقية
184.11 M
نطاق اليوم
KWD 2.19 — KWD 2.29
نطاق 52 أسبوعًا
KWD 1.32 — KWD 3.19
حجم التداول
671,399
فتح KWD 2.25
متوسط 50 يوم / 200 يوم
KWD 2.61
12.30% below
متوسط 50 يوم / 200 يوم
KWD 2.02
12.96% above

Quick Summary

النقاط الرئيسية

Revenue grew 8.29% annually over 5 years — modest growth
Earnings declined -325.24% over the past year
Negative free cash flow of -13.63 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 9.52%
Capital efficient — spends only 3.11% of revenue on capex

النمو

Revenue Growth (5Y)
8.29%
أقل من متوسط القطاع (9.35%)
Revenue (1Y)-1.23%
Earnings (1Y)-325.24%
FCF Growth (3Y)N/A

الجودة

Return on Equity
-12.85%
أعلى من متوسط القطاع (-51.02%)
ROIC-7.58%
Net Margin-12.52%
Op. Margin-10.43%

الأمان

Debt / Equity
N/A
Current Ratio3.03
Interest CoverageN/A

التقييم

PE (TTM)
-27.88
أقل من متوسط القطاع (-1.98)
P/B Ratio3.48
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (44 نظير)
المقياس السهم وسيط القطاع
P/E -27.9 -2.0
P/B 3.5 5.1
ROE % -12.9 -51.0
Net Margin % -12.5 -150.2
Rev Growth 5Y % 8.3 9.3
D/E — 0.3

ETFs Holding This Stock

DEEF logo DEEF Xtrackers FTSE Developed ex US Multifactor ETF
0.06% weight
DBEZ logo DBEZ Xtrackers MSCI Eurozone Hedged Equity ETF
0.02% weight
NTSI logo NTSI WisdomTree International Efficient Core Fund
0.01% weight
GTPE logo GTPE Goldman Sachs MSCI World Private Equity Return Tracker ETF
0.01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -1.23% Revenue Growth (3Y) -10.26%
Earnings Growth (1Y) -325.24% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8.29% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 52.74 M Net Income (TTM) -6.60 M
ROE -12.85% ROA -8.22%
Gross Margin N/A Operating Margin -10.43%
Net Margin -12.52% Free Cash Flow (TTM) -13.63 M
ROIC -7.58% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.03
Interest Coverage N/A Asset Turnover 0.66
Working Capital 44.56 M Tangible Book Value 52.91 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -27.88 Forward P/E N/A
P/B Ratio 3.48 P/S Ratio 3.49
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7.40%
Market Cap 184.11 M Enterprise Value 170.46 M
Per Share
EPS (Diluted TTM) -0.08 Revenue / Share 0.65
FCF / Share -0.17 OCF / Share -0.15
EPS CAGR (1Y) -300.00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 3.11% FCF Conversion 206.41%
SBC-Adj. FCF -15.82 M Growth Momentum -9.52

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 52.74 M 53.40 M 65.49 M 47.64 M 38.35 M
Net Income -6.60 M 2.93 M 8.31 M -14.93 M -27.58 M
EPS (Diluted) -0.08 0.04 0.09 -0.31 -0.62
Gross Profit — — — — —
Operating Income -5.50 M 3.92 M 10.46 M -13.01 M -20.46 M
EBITDA — — — — —
R&D Expenses 19.57 M 12.97 M 17.09 M 29.35 M 29.73 M
SG&A Expenses 11.68 M 12.19 M 14.96 M 11.71 M 12.73 M
D&A — — — — —
Interest Expense — — — — —
Income Tax 996,000.0 1.22 M 254,000.0 530,000.0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 82.35 M 73.42 M 84.43 M 55.79 M 73.67 M
Total Liabilities 34.12 M 30.21 M 50.87 M 66.43 M 79.70 M
Shareholders' Equity 48.23 M 43.21 M 33.57 M -10.64 M -6.04 M
Total Debt — — — — —
Cash & Equivalents 14.68 M 19.76 M 23.63 M 17.11 M 38.99 M
Current Assets 66.67 M 60.08 M 69.93 M 44.88 M 61.67 M
Current Liabilities 26.52 M 25.62 M 45.53 M 32.43 M 33.18 M